Effect of tocilizumab versus standard of care in adults hospitalized with moderate-severe COVID-19 pneumonia

Mostrar otras versiones (1)

INTRODUCTION AND OBJECTIVES: Tocilizumab is an interleukin-6 receptor-blocking agent proposed for the treatment of severe COVID-19; however, limited data are available on their efficacy. The aim of this study was to assess the effect of tocilizumab on the outcomes of patients with COVID-19 pneumonia...

Descripción completa

Detalles Bibliográficos
Autores principales: Cardona-Pascual, Ignacio, Berlana, David, Martinez-Valle, Ferran, Campany-Herrero, David, Montoro-Ronsano, José Bruno
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier España, S.L.U. 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8101781/
https://www.ncbi.nlm.nih.gov/pubmed/34147248
http://dx.doi.org/10.1016/j.medcli.2021.03.005

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8101781/
https://www.ncbi.nlm.nih.gov/pubmed/34147248
http://dx.doi.org/10.1016/j.medcli.2021.03.005

Ejemplares similares